Trial reveals mechanisms that contribute to impact of malnutrition and HIV infection
Severe acute malnutrition is responsible for nearly half of all child deaths globally and affects 17 million children annually
Read More
Tag: budesonide
AZ builds case for fixed-dose albuterol and budesonide combo in asthma
Positive results revealed from two Phase III trials of potential asthma therapy
Read More
Inhaled asthma drug accelerates recovery from COVID-19
Self-reported recovery was three days shorter for patients receiving inhaled budesonide
Read More
AZ Symbicort reduces rate of asthma attacks
The results showed a a 51% reduction in the rate of annual asthma exacerbations compared to albuterol.
Read More
UK launch for first eosinophilic oesophagitis drug
Dr Falk Pharma has launched Jorveza – the first globally licensed drug approved for eosinophilic oesophagitis – across the UK.
Read More
MHRA expands use of Tillotts’ Entocort
The Medicines and Healthcare Products Regulatory Agency (MHRA) has expanded the approved uses of Tillotts Pharma’s Entocort to include the induction of remission in patients with active microscopic colitis (MC).
Read More
Ten new medicines leap towards EU approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use has put 10 medicines forward for approval in the region, including new options for multiple sclerosis, eosinophilic esophagitis and eosinophilic asthma.
Read More
AZ sells nasal spray rights to J&J
AstraZeneca is divesting certain rights to its nasal inflammation spray Rhincort Aqua to Johnson & Johnson group Cilag GmbH International.
Read More
Shire picks up two breakthrough badges for rare disease drugs
US regulators have awarded ‘Breakthrough Therapy’ badges to two investigational products being developed by Shire: a novel formulation of budesonide for eosinophilic esophagitis and maralixibat for progressive familial intrahepatic cholestasis type 2.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
